Big News: FDA is moving from MasterControl to ComplianceQuest.See Why
Talk to a SpecialistLoading…
Talk to a SpecialistTalk to a SpecialistHims & Hers Health was cited for unlawfully selling unapproved and misbranded compounded semaglutide drugs through its website by making false or misleading claims that the products contained "the same active ingredient as Ozempic and Wegovy" and were "clinically proven," violating sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act. The FDA determined that these marketing claims falsely implied the compounded products were equivalent to FDA-approved drugs when compounded drugs are not FDA-approved, constituting misbranding violations under federal law. The company's introduction and delivery of these misbranded products into interstate commerce violated section 301(a) of the FDCA.